{"schema_version":"secwatch.filing_event.v1","accession":"0001601830-23-000009","form_type":"8-K","ticker":"RXRX","cik":"0001601830","company_name":"RECURSION PHARMACEUTICALS, INC.","filed_at":"2023-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.788348+00:00","generated_at":"2026-06-18T23:41:42.630096+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Recursion reports FY2022 net loss $239.5M; cash $549.9M; pipeline advances","bullets":["Net loss of $239.5M for FY2022, up from $186.5M in FY2021; Q4 net loss $57.5M.","Revenue of $39.8M (FY2022) vs $10.2M prior year, driven by Roche-Genentech collaboration.","Cash, cash equivalents and investments $549.9M as of Dec 31, 2022, up from $516.6M.","Initiated five clinical trials in 2022; expects top-line data for REC-994 (CCM) in 2H 2024 and REC-3964 (C. diff) safety/PK data in 2H 2023.","Released RxRx3 open-source cellular imaging dataset and MolRec application in January 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001601830-23-000009","json":"https://secwatch.observer/filing/0001601830-23-000009.json","markdown":"https://secwatch.observer/filing/0001601830-23-000009.md","text":"https://secwatch.observer/filing/0001601830-23-000009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601830/000160183023000009/0001601830-23-000009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601830/000160183023000009/rxrx-20230227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T23:41:42.630096+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cfcb93259347c65d84c66d2f92b2935668bccc19","claim":"RECURSION PHARMACEUTICALS, INC. reported financial results for the fourth quarter and fiscal year ended December 31, 2022.","evidence_excerpt":"On February 27, 2023, Recursion Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its results of operations and financial condition for the fourth quarter and fiscal year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183023000009/0001601830-23-000009-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and fiscal year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}